Ignite Creation Date:
2024-05-06 @ 8:20 AM
Last Modification Date:
2024-10-26 @ 11:58 AM
Study NCT ID:
NCT02714855
Status:
COMPLETED
Last Update Posted:
2017-04-19
First Post:
2016-03-16
Brief Title:
Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France - Cross-sectional Study
Status:
COMPLETED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The present study will be conducted to assess the following research questions in real-life conditions in France
What are the patient and disease characteristics comorbidities and treatment history in NVAF patients initiating a new Anticoagulant AC treatment according to treatment currently available and prescribed apixaban other NOACs VKAs and are the AC-naive patient profiles different from one treatment pattern to another when initiating a new AC treatment
What are the HCPs reasons for discontinuing the previous AC strategy for initiating and choosing the newly initiated AC treatment in NVAF patients
What are the conditions of newly-initiated apixaban prescriptions in NVAF patients prescriber proportion of naïveexperienced patients daily dosage and number of daily doses
What are the patient and disease characteristics comorbidities and treatment history in NVAF patients initiating a new Anticoagulant AC treatment according to treatment currently available and prescribed apixaban other NOACs VKAs and are the AC-naive patient profiles different from one treatment pattern to another when initiating a new AC treatment
What are the HCPs reasons for discontinuing the previous AC strategy for initiating and choosing the newly initiated AC treatment in NVAF patients
What are the conditions of newly-initiated apixaban prescriptions in NVAF patients prescriber proportion of naïveexperienced patients daily dosage and number of daily doses
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None